August 27 | 2020 2cureX AB (“2cureX”) hereby publishes the interim report for the first half of 2020. Read more
August 27 | 2020 2cureX AB (”2cureX”) offentliggör härmed halvårsrapport för det första halvåret 2020 Read more
July 13 | 2020 Avstämningsdag för tilldelning av teckningsoptioner av serie TO1 bestämd till den 17 juli 2020 Read more
July 6 | 2020 2cureX completes a heavily oversubscribed directed issue of approximately SEK 40 million Read more
July 6 | 2020 2cureX har genomfört en riktad nyemission om cirka 40 MSEK som blev kraftigt övertecknad Read more
June 25 | 2020 2cureX receives third payment from the EU’ Horizon 2020 SME- Instrument Program Read more
June 25 | 2020 2cureX receives third payment from the EU’ Horizon 2020 SME- Instrument Program Read more
June 16 | 2020 2cureX AB establishes collaboration with Scandion Oncology A/S and Erasmus Medical Centre, Rotterdam, in drug-resistant breast cancer patients Read more
June 16 | 2020 2cureX AB establishes collaboration with Scandion Oncology A/S and Erasmus Medical Centre, Rotterdam, in drug-resistant breast cancer patients Read more